Category

Daily Briefs

Daily Brief India: Pine Labs and more

By | Daily Briefs, India

In today’s briefing:

  • Pinelabs IPO Review – Another Fintech IPO Exactly 4yrs After Paytm – Can It Buck the Trend?


Pinelabs IPO Review – Another Fintech IPO Exactly 4yrs After Paytm – Can It Buck the Trend?

By Himanshu Dugar

  • Pine Labs is a fintech company supporting digitization of commerce through digital payments and issuing solutions for merchants, consumer brands and enterprises, and financial institutions.
  • While the company has been growing in line with peers, its focus on enterprise customers and subscription pricing stands out, while peers have focused on merchants with a %-fee model.
  • IPO priced at sharp discount to expectations ($2.5bn vs $6bn), which is fair given changing business/industry dynamics. Pending RBI investigation and potential selling from early investors are other near-term concerns.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: Lion Rock Group, BeiGene and more

By | China, Daily Briefs

In today’s briefing:

  • Primer: Lion Rock Group (1127 HK) – Nov 2025
  • China Healthcare Weekly (Nov.9)-Medical Insurance “Warning Lines”, NewCo Model, BeiGene 25Q3 Results


Primer: Lion Rock Group (1127 HK) – Nov 2025

By αSK

  • Lion Rock Group is a global printing services provider with a strong foothold in the international book publishing market, demonstrating consistent revenue growth and robust cash flow generation.
  • The company faces headwinds from the secular decline of traditional print media but is actively pursuing growth through strategic acquisitions and operational diversification, particularly in Australia and Southeast Asia.
  • Valuation appears attractive, with low earnings multiples and a high dividend yield, suggesting a value proposition for investors, balanced against the inherent risks of the evolving printing industry.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


China Healthcare Weekly (Nov.9)-Medical Insurance “Warning Lines”, NewCo Model, BeiGene 25Q3 Results

By Xinyao (Criss) Wang

  • The medical insurance fund has crossed certain “warning lines”. Therefore, it is inevitable that the measures to control costs at the expenditure end will be further tightened.
  • We are actually not optimistic about the NewCo model, because domestic pharmaceutical companies may not necessarily be able to share much of Newco’s future development achievements in the end.
  • BeiGene’s 25Q3 results beat expectations. However, there’s no next blockbuster that can drive BeiGene to a big step forward, this is why the market is reluctant to offer higher valuation.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief United States: Omada Health, Serve Robotics, Shutterstock Inc and more

By | Daily Briefs, United States

In today’s briefing:

  • Omada Health (OMDA.US): Robust 3Q Undermined by Sentiment, Long-Term Bullish Thesis Intact
  • Primer: Serve Robotics (1234 US) – Nov 2025
  • Primer: Shutterstock Inc (SSTK US) – Nov 2025


Omada Health (OMDA.US): Robust 3Q Undermined by Sentiment, Long-Term Bullish Thesis Intact

By Andrei Zakharov

  • Omada Health reported stronger than expected 3Q25 revenue of ~$68M (consensus: $61.2M) and management provided guidance for 2025 revenue of $251.5M-$254.5M, +49% y/y at midpoint.  
  • The chronic disease management company introduced Meal Map, a new AI-powered nutrition tool integrated within the Omada Health’s cardiometabolic programs.
  • I’m updating OMDA model estimates in my insight to reflect the company’s 3Q25 results, management guidance, and trends in the digital therapeutics space.

Primer: Serve Robotics (1234 US) – Nov 2025

By αSK

  • Serve Robotics is a key player in the nascent autonomous sidewalk delivery market, with a strategic focus on last-mile food and grocery delivery.
  • The company’s growth is underpinned by significant partnerships with major food delivery platforms, Uber Eats and DoorDash, providing immediate access to a large volume of orders.
  • While experiencing rapid revenue growth, the company remains unprofitable with significant cash burn, highlighting the high-risk, high-reward nature of this emerging industry. The path to profitability hinges on successful fleet expansion, operational efficiency, and navigating regulatory landscapes.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Shutterstock Inc (SSTK US) – Nov 2025

By αSK

  • Shutterstock is strategically pivoting towards generative AI and data services to counter the secular threats to its core stock content business, a move critical for future growth but with an uncertain payoff.
  • While recent acquisitions like Envato are boosting subscriber numbers and revenue, organic growth in the core content segment is declining, and margins are under pressure from a shifting business mix and competitive intensity.
  • The company’s strong dividend yield and high momentum score reflect shareholder returns and recent market cap growth, but these are juxtaposed against a challenging long-term decline in net income and cash flow, indicating a high-risk, high-reward transition period.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Event-Driven: Last Week In Event SPACE: Mandarin Oriental and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • Last Week In Event SPACE: Mandarin Oriental, Light & Wonder, Cathay Pacific, DeNA
  • Mostly) Asia-Pac M&A: Mayne Pharma, Meilan Airport, ReNew Energy Global, Mandom, Restaurant Brands


Last Week In Event SPACE: Mandarin Oriental, Light & Wonder, Cathay Pacific, DeNA

By David Blennerhassett


Mostly) Asia-Pac M&A: Mayne Pharma, Meilan Airport, ReNew Energy Global, Mandom, Restaurant Brands

By David Blennerhassett


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Thematic (Sector/Industry): APAC Healthcare Weekly (November 9) – Celltrion and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • APAC Healthcare Weekly (November 9) – Celltrion, Dong-A ST, Hanmi Pharm, Boan Bio, Eisai, Otsuka
  • Pine Labs IPO – Building India’s Digital Checkout Future


APAC Healthcare Weekly (November 9) – Celltrion, Dong-A ST, Hanmi Pharm, Boan Bio, Eisai, Otsuka

By Tina Banerjee

  • Celltrion inlicensed two antibody-based new drug candidates for the treatment of autoimmune diseases in KRW1T deal. Dong-A ST received approval for epilepsy drug, Xcopri, developed by SK Biopharmaceuticals in Korea.
  • Hanmi Pharmaceutical will distribute and sell three major COPD treatments developed by Boehringer Ingelheim. Shandong Boan Biotechnology’s marketing application for denosumab biosimilar has been accepted in the UK.  
  • Eisai has settled patent infringement litigation with Torrent Pharmaceuticals related to Lenvima in the U.S. Otsuka Holdings initiated Phase 3 clinical trial evaluating quabodepistat, for the treatment of multidrug-resistant tuberculosis.

Pine Labs IPO – Building India’s Digital Checkout Future

By Sudarshan Bhandari

  • India’s digital payments market is booming, expected to grow from Rs. 116.8 trillion in FY2025 to over Rs. 250 trillion by FY2029.
  • Pine Labs targets India’s 80+ million small and mid-sized merchants with UPI-first devices and sector-specific affordability solutions.
  • India’s largest issuer of gift cards, Pine Labs is also a leading player in checkout affordability and merchant payment solutions.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Equity Bottom-Up: Primer: Lion Rock Group (1127 HK) – Nov 2025 and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • Primer: Lion Rock Group (1127 HK) – Nov 2025
  • Omada Health (OMDA.US): Robust 3Q Undermined by Sentiment, Long-Term Bullish Thesis Intact
  • NEC (6701 JP): Tie-Up with Siemens Adds to Growth Potential
  • China Healthcare Weekly (Nov.9)-Medical Insurance “Warning Lines”, NewCo Model, BeiGene 25Q3 Results
  • Mitsui & Co. (8031 JP): Bullish View Reinforced — Copper & LNG Re-Rate Now Structural
  • Primer: Macnica Holdings Inc (3132 JP) – Nov 2025
  • Primer: Serve Robotics (1234 US) – Nov 2025
  • Taiwan Dual-Listings Monitor: TSMC Premium Eases Down; UMC & CHT Opportunity Levels
  • Maersk Q325 Results: Core Ocean Down 55% Y/Y | Downbeat Guidance from Management | Q425 Losses?
  • Primer: Bitfarms (BITF US) – Nov 2025


Primer: Lion Rock Group (1127 HK) – Nov 2025

By αSK

  • Lion Rock Group is a global printing services provider with a strong foothold in the international book publishing market, demonstrating consistent revenue growth and robust cash flow generation.
  • The company faces headwinds from the secular decline of traditional print media but is actively pursuing growth through strategic acquisitions and operational diversification, particularly in Australia and Southeast Asia.
  • Valuation appears attractive, with low earnings multiples and a high dividend yield, suggesting a value proposition for investors, balanced against the inherent risks of the evolving printing industry.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Omada Health (OMDA.US): Robust 3Q Undermined by Sentiment, Long-Term Bullish Thesis Intact

By Andrei Zakharov

  • Omada Health reported stronger than expected 3Q25 revenue of ~$68M (consensus: $61.2M) and management provided guidance for 2025 revenue of $251.5M-$254.5M, +49% y/y at midpoint.  
  • The chronic disease management company introduced Meal Map, a new AI-powered nutrition tool integrated within the Omada Health’s cardiometabolic programs.
  • I’m updating OMDA model estimates in my insight to reflect the company’s 3Q25 results, management guidance, and trends in the digital therapeutics space.

NEC (6701 JP): Tie-Up with Siemens Adds to Growth Potential

By Scott Foster

  • NEC and Siemens plan to develop an automated robot teaching system for faster set-up and more efficient operation of production lines incorporating multiple robots.
  • NEC’s FY Mar-26 guidance raised on strong 1H results. BluStellar, which includes digital twins for robot teaching, grew faster than expected.  
  • Aerospace/Defense led sales growth and followed BluStellar in operating profit. Improving product mix and rising Japanese defense budget point to growing long-term potential.

China Healthcare Weekly (Nov.9)-Medical Insurance “Warning Lines”, NewCo Model, BeiGene 25Q3 Results

By Xinyao (Criss) Wang

  • The medical insurance fund has crossed certain “warning lines”. Therefore, it is inevitable that the measures to control costs at the expenditure end will be further tightened.
  • We are actually not optimistic about the NewCo model, because domestic pharmaceutical companies may not necessarily be able to share much of Newco’s future development achievements in the end.
  • BeiGene’s 25Q3 results beat expectations. However, there’s no next blockbuster that can drive BeiGene to a big step forward, this is why the market is reluctant to offer higher valuation.

Mitsui & Co. (8031 JP): Bullish View Reinforced — Copper & LNG Re-Rate Now Structural

By Rahul Jain

  • 1H FY26 results resilient: LNG and FX offset metals softness; FY26 NI raised 6% to ¥820 bn, ROE ~13%.
  • Valuation gap to Itochu closed; Mitsui now trades ~1.4× P/B with superior copper and LNG leverage.
  • Sustained buybacks (~5% p.a.) and ≥10% Berkshire anchor ensure 6–9% TSR CAGR, with 10%+ if copper >US$10k/t.

Primer: Macnica Holdings Inc (3132 JP) – Nov 2025

By αSK

  • Macnica is a leading Japanese technology distributor specializing in semiconductors and network equipment, well-positioned to capitalize on long-term growth in AI, IoT, and automotive sectors.
  • The company is strategically shifting towards a higher-margin ‘Services & Solutions’ model, expanding beyond traditional distribution to include proprietary products and cybersecurity services.
  • While facing near-term headwinds from semiconductor market cyclicality and margin pressure, Macnica maintains a strong balance sheet, attractive dividend yield, and a valuation that appears reasonable compared to global peers.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Serve Robotics (1234 US) – Nov 2025

By αSK

  • Serve Robotics is a key player in the nascent autonomous sidewalk delivery market, with a strategic focus on last-mile food and grocery delivery.
  • The company’s growth is underpinned by significant partnerships with major food delivery platforms, Uber Eats and DoorDash, providing immediate access to a large volume of orders.
  • While experiencing rapid revenue growth, the company remains unprofitable with significant cash burn, highlighting the high-risk, high-reward nature of this emerging industry. The path to profitability hinges on successful fleet expansion, operational efficiency, and navigating regulatory landscapes.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Taiwan Dual-Listings Monitor: TSMC Premium Eases Down; UMC & CHT Opportunity Levels

By Vincent Fernando, CFA

  • TSMC: +21.8% Premium; Wait for Lower Premium Before Fresh Long
  • UMC: +2.2% Premium; Good Level to Short the ADR Premium
  • CHT: -2.0% Discount; Near Level to Go Long the ADR Spread

Maersk Q325 Results: Core Ocean Down 55% Y/Y | Downbeat Guidance from Management | Q425 Losses?

By Daniel Hellberg

  • Core “Ocean” EBITDA fell by 55% Y/Y in Q325 due to lower average freight rates
  • Maersk lifted lower end of guidance range, but offered downbeat tone on Q4, 2026
  • Shares fell by 5% in response to Thursday’s report; we remain negative on sector

Primer: Bitfarms (BITF US) – Nov 2025

By αSK

  • Bitfarms is a vertically integrated Bitcoin mining company aggressively expanding its operational footprint in North America and diversifying into High-Performance Computing (HPC) and AI infrastructure to create new, stable revenue streams.
  • The company’s strategy hinges on leveraging low-cost, primarily renewable energy sources to maintain competitiveness in a post-halving environment, where operational efficiency is paramount for profitability.
  • Significant financial risks exist, including a history of net losses, high stock volatility, and execution risk associated with its capital-intensive pivot to the AI/HPC sector, alongside its inherent exposure to the volatile price of Bitcoin.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: Lion Rock Group, Mitsui & Co Ltd, AP Moeller – Maersk A/S, Fincantieri SpA, Norwegian Air Shuttle and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Primer: Lion Rock Group (1127 HK) – Nov 2025
  • Mitsui & Co. (8031 JP): Bullish View Reinforced — Copper & LNG Re-Rate Now Structural
  • Maersk Q325 Results: Core Ocean Down 55% Y/Y | Downbeat Guidance from Management | Q425 Losses?
  • Primer: Fincantieri SpA (FCT IM) – Nov 2025
  • Primer: Norwegian Air Shuttle (NAS NO) – Nov 2025


Primer: Lion Rock Group (1127 HK) – Nov 2025

By αSK

  • Lion Rock Group is a global printing services provider with a strong foothold in the international book publishing market, demonstrating consistent revenue growth and robust cash flow generation.
  • The company faces headwinds from the secular decline of traditional print media but is actively pursuing growth through strategic acquisitions and operational diversification, particularly in Australia and Southeast Asia.
  • Valuation appears attractive, with low earnings multiples and a high dividend yield, suggesting a value proposition for investors, balanced against the inherent risks of the evolving printing industry.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Mitsui & Co. (8031 JP): Bullish View Reinforced — Copper & LNG Re-Rate Now Structural

By Rahul Jain

  • 1H FY26 results resilient: LNG and FX offset metals softness; FY26 NI raised 6% to ¥820 bn, ROE ~13%.
  • Valuation gap to Itochu closed; Mitsui now trades ~1.4× P/B with superior copper and LNG leverage.
  • Sustained buybacks (~5% p.a.) and ≥10% Berkshire anchor ensure 6–9% TSR CAGR, with 10%+ if copper >US$10k/t.

Maersk Q325 Results: Core Ocean Down 55% Y/Y | Downbeat Guidance from Management | Q425 Losses?

By Daniel Hellberg

  • Core “Ocean” EBITDA fell by 55% Y/Y in Q325 due to lower average freight rates
  • Maersk lifted lower end of guidance range, but offered downbeat tone on Q4, 2026
  • Shares fell by 5% in response to Thursday’s report; we remain negative on sector

Primer: Fincantieri SpA (FCT IM) – Nov 2025

By αSK

  • Fincantieri is a global leader in shipbuilding, specializing in high-value-added segments such as cruise ships, defense vessels, and specialized offshore vessels. The company is well-positioned to benefit from the ongoing recovery in the cruise industry and increasing global defense budgets.
  • Recent financial performance has shown significant improvement, with strong revenue and EBITDA growth, driven by a record order intake and a substantial backlog that provides long-term visibility. The company is also strategically expanding into the high-margin underwater and submarine sector.
  • Key challenges include managing a high debt load, navigating the cyclicality of the shipbuilding industry, and addressing operational efficiencies to improve profitability margins further. The company’s valuation appears elevated compared to peers, suggesting high growth expectations are priced in.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Norwegian Air Shuttle (NAS NO) – Nov 2025

By αSK

  • Following a comprehensive restructuring that saw the company exit bankruptcy protection, Norwegian Air Shuttle has successfully pivoted from a struggling long-haul carrier to a focused, profitable Nordic-based low-cost airline.
  • The company has demonstrated a significant financial turnaround, with strong revenue growth and a return to profitability, driven by renewed travel demand and a disciplined operational strategy. However, the balance sheet remains leveraged.
  • Intense competition from larger European low-cost carriers and volatility in fuel prices and currency exchange rates represent the most significant headwinds to sustained profitability and future growth.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: Light & Wonder , Zhejiang Leapmotor Technologie, Asian Paints, Yum China Holdings , Robotis, China Northern Rare Earth Group High-Tech, All Winner Technology, Pine Labs, Hang Seng Index and more

By | Daily Briefs, Most Read

In today’s briefing:

  • Light & Wonder (LNW AU): Index Implications of NASDAQ Delisting & ASX Primary Listing
  • HSTECH Index Rebalance Preview: Can Leapmotor Leap into the Index?
  • India: Potential Free Float Changes & Passive Flows in November
  • HSCEI Index Rebalance Preview: 3 Changes as Adds Go Up, Up & Away
  • KOSDAQ150 Index Rebalance Preview: Large Number of Changes Likely in December; Huge Outperformance
  • SSE50 Index Rebalance Preview: 4 Potential Changes in December
  • CES China Semiconductor Chips Index Rebalance Preview: One Change Likely in Dec
  • HEW: Caution Echoes Outside the BoE
  • Pinelabs IPO Review – Another Fintech IPO Exactly 4yrs After Paytm – Can It Buck the Trend?
  • Hong Kong Single Stock Options Weekly (Nov 03–07): Growing Split Between Old and New Economy Sectors


Light & Wonder (LNW AU): Index Implications of NASDAQ Delisting & ASX Primary Listing

By Brian Freitas


HSTECH Index Rebalance Preview: Can Leapmotor Leap into the Index?

By Brian Freitas


India: Potential Free Float Changes & Passive Flows in November

By Brian Freitas

  • Companies in India have disclosed their shareholding pattern as of end-September in October. There are companies with significant float changes from end-June and/or end-March.
  • The changes in free float could be reflected in domestic and global indices over the next few weeks and months resulting in flow from passive trackers.
  • Depending on the date that the shareholding was published, there could be 20 stocks with passive inflows from global trackers while 6 could have passive outflows in November.

HSCEI Index Rebalance Preview: 3 Changes as Adds Go Up, Up & Away

By Brian Freitas

  • There could be 3 changes for the Hang Seng China Enterprises Index (HSCEI INDEX) in December. Announcement is on 21 November with implementation at the close on 5 December.
  • The forecast adds have moved higher over the last few months and handily outperformed the forecast deletes and the Hang Seng China Enterprises Index (HSCEI INDEX)
  • There has been aggressive short covering in the forecast adds and there could be more in stocks where short interest is still a high percentage of float.

KOSDAQ150 Index Rebalance Preview: Large Number of Changes Likely in December; Huge Outperformance

By Brian Freitas

  • With the review period for the December rebalance complete, we highlight 17 potential changes for the KOSDAQ 150 Index (KOSDQ150 INDEX)
  • The estimated impact on the potential inclusions ranges from 0.1-3.2 days of ADV while the impact on the potential deletions varies from 0.7-11.2 days of ADV.
  • The forecast adds have outperformed the forecast deletes over the last 6 months with a big move higher in the last couple of months. Trim positions into strength.

SSE50 Index Rebalance Preview: 4 Potential Changes in December

By Brian Freitas

  • With the review period complete, there are 6 non-constituents in direct inclusion zone and 4 current constituents in direct deletion zone. However, as usual, there will be discretion used.
  • 4 changes result in a one-way turnover of 4%, leading to a round-trip trade of CNY 17bn (US$2.4bn). Index arb balances will increase the impact on the stocks.
  • The index committee has used discretion in selecting the index adds and deletes and that could continue to be the case at this review too.

CES China Semiconductor Chips Index Rebalance Preview: One Change Likely in Dec

By Brian Freitas


HEW: Caution Echoes Outside the BoE

By Phil Rush

  • The BoE resisted cavalier calls for a rate cut this week, but it is much less cautious than we expected. A December rate cut is now likely, absent significant upside surprises.
  • All other central bank announcements this week fit the trend, with cautious holds in Australia, Sweden, Norway, Malaysia and Brazil, and a more careful cut in Mexico.
  • Next week’s UK labour market (and GDP) data are one of the few things that could clear the evidential hurdle to block a cut, although we doubt good news will extend that far.

Pinelabs IPO Review – Another Fintech IPO Exactly 4yrs After Paytm – Can It Buck the Trend?

By Himanshu Dugar

  • Pine Labs is a fintech company supporting digitization of commerce through digital payments and issuing solutions for merchants, consumer brands and enterprises, and financial institutions.
  • While the company has been growing in line with peers, its focus on enterprise customers and subscription pricing stands out, while peers have focused on merchants with a %-fee model.
  • IPO priced at sharp discount to expectations ($2.5bn vs $6bn), which is fair given changing business/industry dynamics. Pending RBI investigation and potential selling from early investors are other near-term concerns.

Hong Kong Single Stock Options Weekly (Nov 03–07): Growing Split Between Old and New Economy Sectors

By John Ley

  • Markets steadied in North America suggesting a firmer open for Hong Kong stock on Monday.
  • Hong Kong market breadth improved notably, suggesting broader participation despite uneven performance across sectors.
  • Option activity eased slightly, though Call demand remained steady relative to overall volume.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief Energy/Materials: Seadrill Ltd and more

By | Daily Briefs, Energy & Materials Sector

In today’s briefing:

  • Primer: Seadrill Ltd (SDRL NO) – Nov 2025


Primer: Seadrill Ltd (SDRL NO) – Nov 2025

By αSK

  • Seadrill has emerged from restructuring with a strengthened balance sheet and a strategic focus on its high-specification, modern fleet of offshore drilling rigs, positioning it to capitalize on the current industry upcycle.
  • The company has demonstrated commercial success by securing over $300 million in new contracts in Q3 2025, contributing to a robust order backlog of approximately $2.5 billion, which provides significant revenue visibility into 2026.
  • Despite a favorable market outlook with rising dayrates, Seadrill faces challenges including recent quarterly net losses, high operational risks, and intense competition, underscoring the inherent volatility of the offshore drilling sector.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Omada Health, BeiGene and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Omada Health (OMDA.US): Robust 3Q Undermined by Sentiment, Long-Term Bullish Thesis Intact
  • China Healthcare Weekly (Nov.9)-Medical Insurance “Warning Lines”, NewCo Model, BeiGene 25Q3 Results


Omada Health (OMDA.US): Robust 3Q Undermined by Sentiment, Long-Term Bullish Thesis Intact

By Andrei Zakharov

  • Omada Health reported stronger than expected 3Q25 revenue of ~$68M (consensus: $61.2M) and management provided guidance for 2025 revenue of $251.5M-$254.5M, +49% y/y at midpoint.  
  • The chronic disease management company introduced Meal Map, a new AI-powered nutrition tool integrated within the Omada Health’s cardiometabolic programs.
  • I’m updating OMDA model estimates in my insight to reflect the company’s 3Q25 results, management guidance, and trends in the digital therapeutics space.

China Healthcare Weekly (Nov.9)-Medical Insurance “Warning Lines”, NewCo Model, BeiGene 25Q3 Results

By Xinyao (Criss) Wang

  • The medical insurance fund has crossed certain “warning lines”. Therefore, it is inevitable that the measures to control costs at the expenditure end will be further tightened.
  • We are actually not optimistic about the NewCo model, because domestic pharmaceutical companies may not necessarily be able to share much of Newco’s future development achievements in the end.
  • BeiGene’s 25Q3 results beat expectations. However, there’s no next blockbuster that can drive BeiGene to a big step forward, this is why the market is reluctant to offer higher valuation.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars